Gland Pharma Ltd has entered into a strategic manufacturing and supply agreement (MSA) with a leading global pharmaceutical company for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for international markets.
The agreement strengthens Gland Pharma’s position as an integrated end-to-end contract development and manufacturing organisation (CDMO), covering multiple products across different stages of their lifecycle, including commercially marketed products and pipeline products under development.
The partnership follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply of sterile injectable products.
55 SKUs across three sites
The portfolio covers a diversified range of oncology and non-oncology products across vials, lyophilised (lyo) products, ampoules and pre-filled syringes (PFS).
It includes both complex and conventional injectable formulations, enabling Gland Pharma to leverage its capabilities across product development, technology transfer, manufacturing, quality and regulatory support.
Under the agreement, Gland Pharma will provide an integrated “one-stop” solution to its partner, covering multiple requirements across the product lifecycle.
The current agreement covers 55 SKUs to be manufactured across three Gland Pharma sites, with scope for additional products to be added to the portfolio.
$100 million revenue potential
The agreement is expected to provide significant long-term business visibility for Gland Pharma, with revenue generation anticipated to begin in calendar year 2029.
Once all products covered under the agreement are commercialised, the portfolio is expected to have an annualised revenue potential of approximately $90 million-$100 million.
Technology transfer activities are expected to be completed within two years, with commercial revenues expected to commence from 2029.
The agreement is therefore expected to strengthen Gland Pharma’s CDMO business while providing greater visibility over future manufacturing and supply revenues.
Strengthening global CDMO play
The collaboration marks another step in Gland Pharma’s strategy of expanding its role beyond conventional contract manufacturing towards a broader, integrated CDMO model.
By combining development, technology transfer, manufacturing, quality and regulatory capabilities, the company aims to provide global pharmaceutical companies with a single partner for sterile injectable products throughout their lifecycle.
Gland Pharma Ltd Executive Chairman Srinivas Sadu said the agreement reflects the confidence global pharmaceutical companies have in the company’s development, technology transfer, manufacturing and supply capabilities.
“The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma’s development, technology transfer, manufacturing, and supply capabilities,” Sadu said.
He added that the agreement provides meaningful long-term revenue visibility, supports expansion of Gland Pharma’s CDMO business and creates a strong foundation for future growth.
“We remain committed to investing in the capabilities and capacity required to support our partner’s evolving needs and ensure reliable supply to patients worldwide,” Sadu said.
With 55 SKUs already covered and additional products potentially being added, the agreement could provide Gland Pharma with a sizeable pipeline of manufacturing opportunities while strengthening its position as a global partner for sterile injectable development and supply.